Santhera Pharmaceuticals Holding AG
SIX:SANN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Goldsource Mines Inc
LSE:0UYO
|
CA |
|
Chalice Mining Ltd
OTC:CGMLF
|
AU |
|
Logansport Financial Corp.
OTC:LOGN
|
US |
|
S
|
Sasfin Holdings Ltd
XBER:47S
|
ZA |
Santhera Pharmaceuticals Holding AG
Research & Development
Santhera Pharmaceuticals Holding AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
Research & Development
-CHf24.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$284.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-37%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf105.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf94.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf8.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Santhera Pharmaceuticals Holding AG
Glance View
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
See Also
What is Santhera Pharmaceuticals Holding AG's Research & Development?
Research & Development
-24.4m
CHF
Based on the financial report for Jun 30, 2025, Santhera Pharmaceuticals Holding AG's Research & Development amounts to -24.4m CHF.
What is Santhera Pharmaceuticals Holding AG's Research & Development growth rate?
Research & Development CAGR 5Y
9%
Over the last year, the Research & Development growth was -7%. The average annual Research & Development growth rates for Santhera Pharmaceuticals Holding AG have been 10% over the past three years , 9% over the past five years .
